GHRP-2 side effects by evidence tier: the approved diagnostic's labelling, the cortisol, ACTH and prolactin signals from controlled studies, paediatric courses, and what no adult trial has measured.
GHRP-2 (pralmorelin) is unusual among research peptides in having formal safety labelling — but the labelling covers a single 100 µg intravenous dose, given once, in an endocrine clinic. Everything else comes from controlled pharmacology studies of a few hours, two small paediatric courses of eight months, and uncontrolled self-report. This page keeps those tiers apart, because the acute record is strong and the chronic record in adults does not exist. It is a research reference beside the GHRP-2 profile, not a safety assessment or medical advice.
GHRP-2 has been given to hundreds of people in endocrine studies since the early 1990s and, since its Japanese approval, as a routine diagnostic. Chihara and colleagues (European Journal of Endocrinology, 2007) validated the 100 µg intravenous test against insulin-tolerance testing in adults, and the product labelling records what that bolus does: transient facial flushing, warmth, sweating, mild headache, hunger and occasionally nausea, typically lasting minutes, plus a small rate of injection-site reactions. Comparative studies in healthy volunteers describe the same short list. In single-dose settings no serious adverse event attributable to the peptide has been reported. That is a genuine finding, and it is also a narrow one: it describes one dose, once, under observation.
GHRP-2 is the most potent GH releaser of the classic GHRPs and also the least selective. Arvat and colleagues in Turin (Peptides, 1997) compared GHRP-2 and hexarelin with GHRH, TRH and hCRH in healthy adults and found that both peptides raised prolactin, ACTH and cortisol alongside a GH peak larger than GHRH produced alone. The rises after a single dose were modest, and the mechanism is understood: the ghrelin receptor is expressed in the hypothalamus and on pituitary lactotrophs as well as somatotrophs, so a strong agonist recruits the adrenal and prolactin axes too. Ipamorelin was designed specifically to remove this property, and within the family GHRP-2 sits at the high-cortisol end — larger than GHRP-6, far larger than ipamorelin.
What has not been measured is what repeated daily stimulation of those axes does in adults. A modest cortisol rise once is one thing; the same rise two or three times daily for months is a different exposure, and no study has followed it. Any statement about GHRP-2's effect on adrenal function, menstrual regularity, libido or mood under chronic dosing is inference.
Laferrère and colleagues (Journal of Clinical Endocrinology & Metabolism, 2005) infused GHRP-2 at 1 µg/kg per hour in healthy men and found they ate substantially more at a test meal, reproducing the effect of ghrelin itself. The appetite signal is reliable and can be pronounced, though GHRP-2 is generally placed between the strongly orexigenic GHRP-6 and the more neutral ipamorelin. Whether that translates into weight gain under repeated dosing has not been studied.
The only months-long human dosing data belongs to GH-deficient children. Mericq and colleagues (Journal of Clinical Endocrinology & Metabolism, 1998) gave subcutaneous GHRP-2 at 0.3 to 3 µg/kg once or twice daily for eight months; Pihoker and colleagues (same journal, 1998) ran the Phase 1 pharmacokinetic study in the same population. Neither reported a serious adverse event attributable to the drug. Both were small, in a specific endocrine disorder, in patients monitored throughout, and the subjects were children. The one pharmacodynamic signal worth carrying forward is attenuation: frequent GHRP administration has been reported to blunt the GH response over days to weeks, which is why those studies dosed intermittently. That is a loss of effect rather than an adverse event, but it is a documented consequence of repeated exposure.
There is no controlled human safety data for GHRP-2 in adults beyond single doses. Specifically absent:
Outside the literature, community reports describe water retention, tingling in the hands, lethargy and persistent hunger. These are unblinded, uncontrolled, and have no denominator; they can generate hypotheses but cannot establish incidence or causation. The research overview covers the mechanism behind each of these signals, and the GHRP-2 vs GHRP-6 comparison sets the two profiles side by side.
Some share of reactions in unregulated use plausibly traces to the vial rather than the molecule. Two problems are specific to GHRP-2. First, identity: it shares four of six residues with GHRP-6 and is sold by the same suppliers, so HPLC purity alone cannot show which compound is in the vial — mass-spectrometry identity can, and a certificate of analysis worth reading includes it. Second, degradation: the tryptophan and naphthylalanine residues make GHRP-2 more light-sensitive than most peptides, so a reconstituted vial left in the light is a different material from a fresh one. Every lot of GHRP-2 5MG is third-party tested, as described under lab testing and COAs, and the cold-chain and shelf-life guide covers the storage side.
GHRP-2 has no Health Canada market authorisation and no DIN, and is sold in Canada for research use only; its Japanese approval as a diagnostic has no bearing here. In September 2023 the U.S. FDA placed GHRP-2 in category 2 of its section 503A compounding evaluation, citing the absence of adequate human safety data for chronic use — the same gap this page describes. The World Anti-Doping Agency lists growth hormone-releasing peptides under S2 and names pralmorelin explicitly, so it is prohibited for tested athletes at all times.
What side effects does the GHRP-2 diagnostic labelling record? Transient flushing, warmth, sweating, mild headache, hunger and occasional nausea after a single 100 µg intravenous dose, lasting minutes, plus a small rate of injection-site reactions. No serious adverse events are attributed to the peptide in single-dose settings.
Does GHRP-2 raise cortisol? Yes, acutely. The 1997 Turin comparison found GHRP-2 raised ACTH, cortisol and prolactin alongside GH after a single dose. The rises were modest, and their consequence under repeated adult dosing has not been studied.
How does GHRP-2 compare with ipamorelin on side effects? Ipamorelin was engineered to release GH without the cortisol and prolactin rise GHRP-2 produces, and has a milder appetite effect. GHRP-2 releases more GH per dose and carries the stronger hormonal signals.
Is there long-term safety data for GHRP-2? Only two small eight-month studies in GH-deficient children, which reported no serious adverse events. There is no repeated-dose safety data in adults by any route.
Is this medical advice? No. GHRP-2 is a research-grade compound for laboratory use only, not for human or veterinary use. This page summarises what published studies and product labelling recorded; it is not a safety assurance, a risk assessment or a recommendation.
